|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Grant Revenue | |||||
| Operating Expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Total Operating Expenses | |||||
| Total Operating Loss | |||||
| Other Income (Expense): | |||||
| Research and development tax credit | |||||
| Research and development credit | |||||
| Interest expense | |||||
| Total Other Income (Expense), Net | |||||
| Net Loss | |||||
| Net Loss attributable to noncontrolling interest | |||||
| Net Loss attributable to common stockholders | |||||
| Basic Loss Per Common Share | |||||
| Diluted Loss Per Common Share | |||||
| Weighted Average Number of Common Shares Outstanding - Basic | |||||
| Weighted Average Number of Common Shares Outstanding - Diluted | |||||
Loading...